Showing papers by "Tata Memorial Hospital published in 1984"

Effect of retinoic acid on bone-marrow committed stem cells (CFU-c) from chronic myeloid leukemia patients.

Abstract: The effect of retinoic acid (all-trans) on the clonal growth of chronic myeloid leukemia marrow was studied. The results indicate that 3 X 10(-5) M, 3 X 10(-6) M, 3 X 10(-7) M and 3 X 10(-8) M of retinoic acid inhibits the colony stimulating activity of placental conditioned medium.

Management of Hodgkin's disease in Western India

Abstract: The authors report a retrospective analysis of 441 patients with Hodgkin's disease seen at the Tata Memorial Hospital, Bombay, over a 4-year period from 1975 to 1978 Clinicopathologic features seem to vary from those reported in the western literature, but are similar to the patterns observed in Africa and South America Thirty-three percent of all malignant lymphomas were Hodgkin's disease Histologically, the mixed cell (MC) type (40%) and the lymphocytic predominant (LP) type (24%) were the most common, with 52% of patients presenting in Stages III and IV The nodular sclerosis (NS) variant occurred in only 11% of the cases Systemic symptoms were present in 24% of clinical Stage I patients, and increased steadily to 85% in Stage IV patients Bone marrow biopsies in 242 patients were found to be of little value in Stages I and II Thirty of 34 patients with positive bone marrow biopsy were in clinical Stages III B and IV, whereas 24 of 34 patients showed MC and LD patterns Lymphangiography in 104 patients altered the clinical staging of Stages I and II in 27% of the cases with accuracy of 80% Staging laparotomy performed in 93 patients altered the stage in 45% of clinical Stage I and 62% of Stage II patients Splenic involvement was common in the presence of systemic symptoms (67%) and MC/LD histology (82%) The incidence of liver involvement was 16% in 15 patients with all, but one, associated with splenic pathology The clinical stage and histopathologic variants of the disease bear an excellent correlation with a significant impact on treatment responses and total survival The survival rates for Stage I were 81%, Stage II 76%, Stage IIIA 71%, and Stage IIIB and IV 46% at 48 months The LP type had the best prognosis with 85% survival at 48 months, whereas the survival in the depleted variety was only 56% Surprisingly, the MC type did better with a 64% survival, while the nodular sclerosis group had 59% surviving at 48 months

GM 58/8: a monoclonal antibody that identifies a new lineage-specific determinant expressed by myeloid progenitors (CFU-GM) and their progeny.

Abstract: SUMMARY A cytotoxic (IgM) monoclonal antibody (McAb) raised against human erythroleukaemia cell line HEL appears specific for the myelomonocytic lineage. Indirect immunofluorescence and fluorescence-activated cell sorter analyses of peripheral blood and bone marrow cells showed that this McAb (designated GM 58/8) reacts exclusively with more than 90% of the granulocytes, monocytes and myeloid precursors. The positive (fluorescent) fraction sorted from McAb-treated bone marrow buffy coat cells showed a marked enrichment of myeloid precursors, while nonmyeloid cells were recovered in the negative fraction. GM 58/8 specifically inhibited the growth of 90-100% of the committed myelomonocytic progenitors (CFU-GM) in five complement-mediated cytotoxicity experiments. GM 58/8 had virtually no effect on the erythroid progenitor (BFU-E and CFU-E) growth. Cell sorting experiments using this McAb resulted in recovery of 84% of CFU-GM among the fluorescent fractions. Comparisons with other anti-myelomonocytic McAbs reported so far suggest that GM 58/8 has more restricted reactivity and shows more efficient CFU-GM cytotoxicity. Patterns of reactivity with normal cells and established lines indicate that the antigenic determinant identified by GM 58/8 is different from that recognized by previously described anti-myelomonocytic McAbs. McAb GM 58/8 could be used to isolate or remove pure populations of progenitors and/or more differentiated cells of the myelomonocytic lineage for in vitro studies. This study also provides evidence that the HEL cell line, derived originally from an erythroleukaemia patient, expresses an antigenic determinant shared by the normal cells of myelomonocytic lineage.

Gastric pull‐up for cancers of the hypopharynx and cervical esophagus: Our experience

Abstract: Twenty-five cases of squamous cancer of the hypopharynx and cervical esophagus treated with laryngopharyngoesophagectomy and pharyngogastric anastomosis are presented. In all cases the lesion was such that a complete circumferential pharyngectomy was necessitated. Twelve patients had received full radiation therapy and surgery was undertaken for residual and recurrent disease. Eleven patients had a concurrent unilateral radical neck dissection and two patients a concurrent bilateral neck dissection. Five patients died within 1 month following surgery. The causes of death are discussed. The most notable features of this method of pharyngeal and cervical esophageal reconstruction is the early restoration of swallowing (20 patients were on oral feed in less than 10 days following surgery), a very low incidence of anastomatic leak and subsequent hazards of a carotid hemorrhage (only one patient had a major leak leading to carotid hemorrhage), and absence of subsequent anastomotic stenosis as is seen after reconstruction with skin tubes.

Vertebral involvement in childhood acute lymphoblastic leukemia.

Abstract: Three cases of acute lymphoblastic leukemia who had multiple vertebral involvement as initial manifestation are presented with review of literature because of its clinical rarity. Importance of early diagnosis and treatment is stressed. In pediatric age group, if there is radiological involvement of vertebrae, then ALL should be considered in the differential diagnosis.